Biodexa Pharmaceuticals Plc

Equities

BDRX

US59564R7089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.3 ^USD	+79.36%		+72.87%	-51.49%

Apr. 26	Sector Update: Health Care Stocks Edge Higher Late Afternoon	MT
Apr. 26	Sector Update: Health Care Stocks Higher in Afternoon Trading	MT

Biodexa Pharmaceuticals Plc Announces Allowance of U.S. Patent Covering Tolimidone

February 07, 2024 at 08:30 am EST

Biodexa Pharmaceuticals PLC announced that the U.S. Patent and Trademark Office allowed U.S. patent application No. 16/546,595 titled Prevention of Pancreatic Cell Degeneration which was exclusively licensed to Biodexa by Melior Pharmaceuticals Inc., along with other patents, in a transaction which closed in December 2023.

Latest news about Biodexa Pharmaceuticals Plc

Sector Update: Health Care Stocks Edge Higher Late Afternoon	Apr. 26	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Apr. 26	MT
European Equities Close Higher in Friday Trading; Anglo American Rejects BHP Takeover Bid	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 24	MT
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	Apr. 23	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
Biodexa Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 19	CI
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Apr. 16	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 08	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
ADRs End Higher, Aesthetic Medical International Holdings Group Ltd. Climbs 35.5%	Apr. 03	DJ
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
ADRs End Lower; NuCana Slides 15%	Mar. 28	DJ
European Equities Close Modestly Higher in Thursday Trading; Data Shows UK Dipped Into Recession in H2 of 2023	Mar. 28	MT

Chart Biodexa Pharmaceuticals Plc

Duration

Period

More charts

Company Profile

Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

Sector

Biotechnology & Medical Research

Calendar

2024-09-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.044 GBP

Average target price

6.337 GBP

Spread / Average Target

+507.17%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIODEXA PHARMACEUTICALS PLC	-51.49%	5.7M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs